Navigation Links
Malaria Drug Doesn't Boost Survival Odds With Prion Diseases
Date:3/11/2009

Oral quinacrine showed no benefit for brain-wasting disorders such as Creutzfeldt-Jakob

WEDNESDAY, March 11 (HealthDay News) -- The drug quinacrine doesn't prolong survival of patients with brain-wasting prion diseases such as Creutzfeldt-Jakob disease (CJD), British researchers say.

Currently, there is no way to prevent or reverse the progression of prion diseases. However, quinacrine -- an oral drug used to treat malaria and some forms of arthritis -- has been shown to be effective in treating prion-infected mouse cells.

This study included 107 patients, aged 12 and older, with prion disease. They underwent neurological assessments and clinical exams at the start of the study and again one, two, four and six months later. After that, the patients were examined every three months.

Some patients started taking 300 milligrams of quinacrine per day at the start of the study, one group started taking the drug later in the study, and others didn't take quinacrine.

During the study, 78 patients died, including 26 who took the drug immediately and 52 who initially took no quinacrine or delayed treatment.

After adjusting for factors such as disease severity and type of prion disease, the researchers found no significant difference in survival rates between those who took quinacrine and those who initially didn't take the drug.

The study was released online and was expected to be published in the April print issue of The Lancet Neurology.

More information

The U.S. National Institute of Allergy and Infectious Diseases has more about prion diseases.



-- Robert Preidt



SOURCE: The Lancet Neurology, news release, March 10, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. Kenyan malaria success strengthens call for free insecticide-treated nets for all
2. MDS Pharma Services Wins Award for Management of Global Malaria Trial
3. How adhesive protein causes malaria
4. Malaria product portfolio would benefit from greater cohesion amongst stakeholders
5. USAID Announces First Malaria Communities Program Grants
6. Collaborative Drug Discovery, Inc. and St. Jude Childrens Research Hospital Make Malaria Research Data Available to Speed Drug Development
7. World Bank Group Report on Malaria in Africa Highlights Progress Towards Goal of Significantly Reducing Malaria Deaths
8. Sanofi Pasteur and Institut Pasteur Team up Against Malaria
9. Bill and Melinda Gates Call for New Global Commitment to Chart a Course for Malaria Eradication
10. Malaria No More and Sumitomo Chemical Help Protect 1.4 Million Kids from Malaria
11. Malaria Vaccine Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Malaria Drug Doesn't Boost Survival Odds With Prion Diseases
(Date:9/22/2017)... ... September 22, 2017 , ... PITTSBURGH...Defibrillators ... often saves lives. However, if one isn’t accessible in certain locations, the risk ... defibrillation, I came up with this idea," said an inventor from Ridgecrest, Calif. ...
(Date:9/22/2017)... ... September 22, 2017 , ... SABRE is pleased ...  , Molli C., a graduate student from Sonora, California, who will begin her ... St. Thomas University in Miami, Florida, was selected from a pool of more ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... rooms is celebrating the one year anniversary of its Houston-Fallbrook facility. , ... Dr. Otinwa, Facility Medical Director of First Choice Emergency Room Houston-Fallbrook. “It has ...
(Date:9/22/2017)... CA (PRWEB) , ... September 22, 2017 , ... ... groceries, wearable, and more products at customers’ doorstep. According to Smart Mart, customers ... Mart has stated to offer wearable, and customers can find clothing at discounted ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process Capability ... p.m. – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , Quality ... run afoul of The Quality System Regulation (§820.250), and Devicemakers find themselves staring ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... , Sept. 9, 2017  Eli Lilly and Company ... and secondary endpoint data for lasmiditan, an investigational, oral, ... demonstrated statistically significant improvements compared to placebo in the ... today at the 18th Congress of the International Headache ... "The data presented today demonstrate lasmiditan,s potential to ...
(Date:9/7/2017)... nearly two decades, New Life Agency has been committed to providing the ... Life Agency announces a powerful three-way partnership designed to deliver substantial savings ... ... http://www.schrafts2.com/ (PRNewsfoto/PharmaCareCard) ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/7/2017)... Sept. 7, 2017 NuvoAir (formerly called ... announced today a partnership with Novartis Pharma AG to distribute ... position as the leading mobile spirometry platform and Novartis, commitment ... ... ...
Breaking Medicine Technology: